GSK has changed. In July 2022, we demerged our world-leading consumer healthcare business, Haleon. We are now a fully focused biopharma company.
We prioritise innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We will focus on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Explore more on our global website below.
Globally, our global portfolio spans vaccines, specialty and general medicines. We’re prioritising R&D investment in vaccines and specialty medicines, which we expect to grow to around three quarters of our global business by 2026.
Globally, our unrivalled vaccine portfolio targets infectious diseases at every stage of life. From adjuvants that improve vaccine effectiveness, through to mRNA technology, we use advanced technologies and collaborate with our partners to develop new, more effective vaccines that help people around the world to get ahead of disease.
Around 40% of the world’s children are immunised against at least one serious disease with a GSK vaccine.
In India, we are #1 in the vaccines self-pay segment. We are committed to protect children, adults and olderly adults against vaccine preventable diseases.
Our Vaccines business currently markets 10 vaccines across age groups for infants, adolescents and adults.
Globally, as our experts seek innovative new ways to treat the human body, specialty medicines are at the forefront of our high-value pipeline of new products. We have leading global positions in developing medicines for respiratory disease and HIV, and we are building our presence in other key therapy areas such as oncology and immunology.
Our Specialty medicines in India are focused on helping patients breathe easy through innovative offerings that combine science and technology.
General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. Globally, this includes our medicines for inhaled respiratory, dermatology, antibiotics and other diseases. These vital medications are the engine room of GSK, supporting hundreds of millions of people to enjoy a better everyday quality of life.
Our General Medicines business in India has a broad portfolio of established medicines with commercial leadership in Anti-infectives, Pain, Dermatology and Vitamins.
Our therapeutic areas
Almost half the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.
Our long-acting HIV medicines have the potential to dramatically change people’s experience by giving them an alternate to daily medicine.
We develop cancer medicines with life-changing potential for patients with ovarian cancer, endometrial cancer and multiple myeloma. We’ve accelerated this research and currently have three marketed therapies and a further nine assets in development.
Our focus on the science of the immune system helps us develop vaccines and medicines for a range of immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in 50 years.
We also pursue other opportunity-driven therapies where the science aligns with our strategic approach. This includes the work we are doing to help the one in seven of the 700 million chronic kidney disease sufferers with anaemia.
Our long-term priorities
Major approvals since 201713
potential new vaccines and medicines in Phase 3 and registration in 201723
vaccines and medicines in our pipeline60+
Patients: packs of medicines and doses of vaccines delivered in 20222.3bn
Shareholders: per share dividend in 202261.25p
Society: corporate income tax paid; in addition we pay duties, levies, transactional and employment taxes£1.3bn
In India, we support our people to help deliver on our ambition for patients, address select national health priorities and widen access to medicines to create value for our stakeholders and society at large.
In India, GSK has always been at the forefront of science and harnesses the power of talent, technology and research to improve the quality of human life. To deliver on our purpose of getting ahead of disease, we rely on our outstanding people, and work hard to create a facilitative environment where they can thrive and achieve exceptional outcomes.
Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing are the foundations for how, together, we’ll deliver for our patients, shareholders and GSK people.
Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.
Ambitious for patients To deliver what matters better and faster Accountable for impact With clear ownership and support to succeed Do the right thing with integrity and care because people count on us. With our new purpose, strategy and culture, we will move #AheadTogether continuing our legacy in General Medicines, our leadership in the Vaccines self-pay market and introduce innovative offerings through our Specialty medicines – all three will help us deliver our ambition for patients and get ahead of disease together.
In India, we will get #AheadTogether with our three priorities